116 related articles for article (PubMed ID: 32460859)
1. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation.
Parry MG; Cowling TE; Sujenthiran A; Nossiter J; Berry B; Cathcart P; Aggarwal A; Payne H; van der Meulen J; Clarke NW; Gnanapragasam VJ
BMC Med; 2020 May; 18(1):114. PubMed ID: 32460859
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study.
Parry MG; Nossiter J; Morris M; Sujenthiran A; Skolarus TA; Berry B; Nathan A; Cathcart P; Aggarwal A; van der Meulen J; Trinh QD; Payne H; Clarke NW
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):287-292. PubMed ID: 35001083
[TBL] [Abstract][Full Text] [Related]
3. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.
Gnanapragasam VJ; Bratt O; Muir K; Lee LS; Huang HH; Stattin P; Lophatananon A
BMC Med; 2018 Feb; 16(1):31. PubMed ID: 29490658
[TBL] [Abstract][Full Text] [Related]
4. Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer.
Gnanapragasam VJ; Barrett T; Thankapannair V; Thurtle D; Rubio-Briones J; Domínguez-Escrig J; Bratt O; Statin P; Muir K; Lophatananon A
BJU Int; 2019 Nov; 124(5):758-767. PubMed ID: 31063245
[TBL] [Abstract][Full Text] [Related]
5. The Effects of O
Yildiz OG; Aslan D; Akalin H; Erdem Y; Canoz O; Aytekin A; Ozoner S; Dundar M
Balkan J Med Genet; 2020 Jun; 23(1):33-41. PubMed ID: 32953407
[TBL] [Abstract][Full Text] [Related]
6. Assessing the impact of MRI based diagnostics on pre-treatment disease classification and prognostic model performance in men diagnosed with new prostate cancer from an unscreened population.
Lophatananon A; Byrne MHV; Barrett T; Warren A; Muir K; Dokubo I; Georgiades F; Sheba M; Bibby L; Gnanapragasam VJ
BMC Cancer; 2022 Aug; 22(1):878. PubMed ID: 35953766
[TBL] [Abstract][Full Text] [Related]
7. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
9. Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.
Zelic R; Garmo H; Zugna D; Stattin P; Richiardi L; Akre O; Pettersson A
Eur Urol; 2020 Feb; 77(2):180-188. PubMed ID: 31606332
[TBL] [Abstract][Full Text] [Related]
10. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
11. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
Berlin A; Moraes FY; Sanmamed N; Glicksman R; Koven A; Espin-Garcia O; Leite ETT; Silva JLF; Gadia R; Nesbitt M; Catton CN; Kaffenberger S; Salami SS; Morgan TM; Hearn JWD; Jackson WC; Mehra R; Chung P; Fleshner NE; Zumsteg ZS; Dess RT; Feng FY; Finelli A; Spratt DE
J Urol; 2019 Feb; 201(2):284-291. PubMed ID: 30153435
[TBL] [Abstract][Full Text] [Related]
12. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
[TBL] [Abstract][Full Text] [Related]
13. Impact of radiation dose on recurrence in high-risk prostate cancer patients.
Deek M; Lilleby W; Vaage V; Hole KH; DeWeese T; Stensvold A; Tran P; Seierstad T
Prostate; 2020 Nov; 80(15):1322-1327. PubMed ID: 33258482
[TBL] [Abstract][Full Text] [Related]
14. What can patient-reported experience measures tell us about the variation in patients' experience of prostate cancer care? A cross-sectional study using survey data from the National Prostate Cancer Audit in England.
Morris M; Cook A; Dodkins J; Price D; Waller S; Hassan S; Nathan A; Aggarwal A; Payne HA; Clarke N; van der Meulen J; Nossiter J
BMJ Open; 2024 Feb; 14(2):e078284. PubMed ID: 38418235
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylation of interleukin-6 (IL-6) gene increases the risk of essential hypertension: a matched case-control study.
Mao SQ; Sun JH; Gu TL; Zhu FB; Yin FY; Zhang LN
J Hum Hypertens; 2017 Aug; 31(8):530-536. PubMed ID: 28300071
[TBL] [Abstract][Full Text] [Related]
16. Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.
Parry MG; Sujenthiran A; Cowling TE; Nossiter J; Cathcart P; Clarke NW; Payne H; Aggarwal A; van der Meulen J
Int J Cancer; 2019 Jul; 145(1):40-48. PubMed ID: 30549266
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer outcomes for men who present with symptoms at diagnosis.
Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
[TBL] [Abstract][Full Text] [Related]
18. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.
Arvold ND; Chen MH; Moul JW; Moran BJ; Dosoretz DE; Bañez LL; Katin MJ; Braccioforte MH; D'Amico AV
J Urol; 2011 Jul; 186(1):91-6. PubMed ID: 21571341
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study.
Kim L; Boxall N; George A; Burling K; Acher P; Aning J; McCracken S; Page T; Gnanapragasam VJ
BMC Med; 2020 Apr; 18(1):95. PubMed ID: 32299423
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
